LBRX
LB Pharmaceuticals Inc
19.82
-0.04-0.2%
Dec 16, 4:00:01 PM EST

Upcoming Earnings 

Report date
≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap
501.43M
P/E (TTM)
-
Basic EPS (TTM)
-0.74
Dividend Yield
0%

Recent Filings

About 

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

CEO
Ms. Heather D. Turner J.D.
IPO
9/11/2025
Employees
16
Sector
Healthcare
Industry
Biotechnology